Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators. Usmani SZ, et al. Among authors: lim abm. Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18. Lancet Haematol. 2019. PMID: 31327689 Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. Spicka I, et al. Eur J Haematol. 2022 Nov;109(5):504-512. doi: 10.1111/ejh.13835. Epub 2022 Aug 18. Eur J Haematol. 2022. PMID: 35871357 Free PMC article.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. Facon T, et al. Hematol Oncol. 2022 Dec;40(5):1020-1029. doi: 10.1002/hon.3038. Epub 2022 Jun 8. Hematol Oncol. 2022. PMID: 35653225 Free PMC article.
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft.
Rees MJ, Mollee P, Ng JY, Murton A, Gonsalves JF, Panigrahi A, Beer H, Loh J, Nguyen P, Hunt S, Jina H, Wayte R, Sutrave G, Tan J, Abeyakoon C, Chee A, Augustson B, Kalro A, Lee C, Agrawal S, Churilov L, Chua CC, Lim ABM, Zantomio D, Grigg A. Rees MJ, et al. Among authors: lim abm. Bone Marrow Transplant. 2021 Sep;56(9):2152-2159. doi: 10.1038/s41409-021-01300-2. Epub 2021 Apr 28. Bone Marrow Transplant. 2021. PMID: 33911199
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse.
Lim ABM, Curley C, Fong CY, Bilmon I, Beligaswatte A, Purtill D, Getta B, Johnston AM, Armytage T, Collins M, Mason K, Fielding K, Greenwood M, Gibson J, Hertzberg M, Wright M, Lewis I, Moore J, Curtis D, Szer J, Kennedy G, Ritchie D. Lim ABM, et al. Intern Med J. 2018 Mar;48(3):276-285. doi: 10.1111/imj.13522. Intern Med J. 2018. PMID: 28628276
Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.
Lim AB, Storek J, Beligaswatte A, Collins M, Tacey M, Williamson T, Mason K, Li E, Chaudhry MA, Russell JA, Daly A, Szer J, Lewis I, Ritchie D. Lim AB, et al. Bone Marrow Transplant. 2015 Apr;50(4):566-72. doi: 10.1038/bmt.2014.313. Epub 2015 Feb 2. Bone Marrow Transplant. 2015. PMID: 25642763 Clinical Trial.
12 results